Abstract 15897: Microalbuminuria is Associated With Subclinical Cardiovascular Disease Parameters Independent of Traditional Risk Factors in a Large Population Based Study
Background: To reduce the burden of cardiovascular disease (CVD), management strategies are increasingly focusing on preventive measures following early detection of markers of CVD. Microalbuminuria (MA) is gaining recognition as a simple marker of CVD. MA is an independent predictor of cardiovascular (CV) mortality, but the association between MA and CVD is not fully defined. In the current study we aimed to assess the relationship between MA and subclinical CVD parameters.
Methods: We conducted a population-based study in 8,080 South Indians, which included morning urine samples for albumin and creatinine levels for calculating MA, glucose tolerance test, anthropometric, physical activity, blood pressure, fasting blood for lipid levels and other biomarker assessments. Other assessments included left ventricular mass indexed (LVMI) to body surface area by echocardiograph, carotid intimal medial thickness (IMT), arterial stiffness by carotid-femoral pulse wave velocity (PWV) and endothelial function by brachial artery flow mediated dilatation (FMD).
Results: After the exclusion of people with evidence of coronary artery disease, 7164 subjects (mean age 43 years, 58% women) constituted the study sample. The value of subclinical CV parameters by MA quartiles is shown in the Table. In univariate analysis MA level was associated with PWV (r = 0.14, P < 0.01), LVMI (r = 0.14, P < 0.01), FMD (r = -0.030, P < 0.01) and IMT (r = 0.077, P < 0.01). In multi-linear models after adjusting for age, sex, smoking, physical activity, BMI, diabetes, hypertension, triglyceride, LDL and HDL levels, MA was independently associated with PWV ( = 0.067, P < 0.01), LVMI ( = 0.091, P < 0.01) and IMT ( = 0.043, P < 0.01).
Conclusion: MA was associated with subclinical CVD parameters independent of traditional CVD risk factors. MA could be a simple marker of subclinical CVD and periodic screening for MA could allow for early identification subclinical disease and intervention.
Author Disclosures: M. Thanikachalam: None. A. Swaminathan: None. J. Sunderarajan: None. V. Harivanzan: None. S. Thanikachalam: None.
- © 2014 by American Heart Association, Inc.